相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Inhibitory Effect of Immunologically Activated Mesenchymal Stem Cells on Lung Cancer Cell Growth and Metastasis
Hong Ye et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2023)
Characterization of a novel Toll-like receptor 13 homologue from a marine fish Nibea albiflora, revealing its immunologic function as PRRs
Yue Liu et al.
DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY (2023)
Inhibition of TLR7 and TLR9 Reduces Human Cholangiocarcinoma Cell Proliferation and Tumor Development
Fatma El Zahraa Mohamed et al.
DIGESTIVE DISEASES AND SCIENCES (2022)
Toll-like receptor 8 agonists improve NK-cell function primarily targeting CD56brightCD16- subset
Irene Veneziani et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Toll-Like Receptors Serve as Biomarkers for Early Diagnosis and Prognosis Assessment of Kidney Renal Clear Cell Carcinoma by Influencing the Immune Microenvironment: Comprehensive Bioinformatics Analysis Combined With Experimental Validation
Xiong Zou et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2022)
A comprehensive model based on temporal dynamics of peripheral T cell repertoire for predicting post-treatment distant metastasis of nasopharyngeal carcinoma
Yajing Zhang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)
The Role of Toll-like Receptors in Esophageal Cancer
Spyridon Davakis et al.
ANTICANCER RESEARCH (2022)
Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy
Lawrence P. Andrews et al.
CLINICAL CANCER RESEARCH (2022)
Targeting toll-like receptors on T cells as a therapeutic strategy against tumors
Renyi Ding et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2022)
The TLR7/8 agonist R848 optimizes host and tumor immunity to improve therapeutic efficacy in murine lung cancer
Jianchun Zhou et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2022)
Cancer vaccines as promising immuno-therapeutics: platforms and current progress
Jian Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)
Molecular dynamics simulations reveal the selectivity mechanism of structurally similar agonists to TLR7 and TLR8
Xiaoyu Wang et al.
PLOS ONE (2022)
The expression and prognostic value of toll-like receptors (TLRs) in pancreatic cancer patients treated with neoadjuvant therapy
Anna Maria Nurmi et al.
PLOS ONE (2022)
Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+ T cell cytotoxicity over BEMPEG plus RT
Annah S. Rolig et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy
Eugene Y. Chiang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Update in TIGIT Immune-Checkpoint Role in Cancer
Tiziana Annese et al.
FRONTIERS IN ONCOLOGY (2022)
Targeting macrophages in hematological malignancies: recent advances and future directions
Wei Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)
A Therapeutic Whole-Tumor-Cell Vaccine Covalently Conjugated with a TLR7 Agonist
Huju Chi et al.
CELLS (2022)
Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin
Shunjie Yu et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2022)
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy
Yi Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)
Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies
Hailong Tian et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)
Epitope Mapping of Therapeutic Antibodies Targeting Human LAG3
Pragati Agnihotri et al.
JOURNAL OF IMMUNOLOGY (2022)
Identification and pharmacological modification of resistance mechanisms to protoporphyrin-mediated photodynamic therapy in human cutaneous squamous cell carcinoma cell lines
Nicole Schary et al.
PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY (2022)
Therapeutic applications of toll-like receptors (TLRs) agonists in AML
Ye Peng et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2022)
Toll-Like Receptor 8 Agonist GS-9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis B
Stephane Daffis et al.
HEPATOLOGY (2021)
A Double-blind, Randomized Phase 2 Controlled Trial of Intradermal Hepatitis B Vaccination With a Topical Toll-like Receptor 7 Agonist Imiquimod, in Patients on Dialysis
Ivan Fan-Ngai Hung et al.
CLINICAL INFECTIOUS DISEASES (2021)
Activation of Toll-like receptor 2 enhances peripheral and tumor-infiltrating CD8(+) T cell cytotoxicity in patients with gastric cancer
Junli Xu et al.
BMC IMMUNOLOGY (2021)
Therapeutic Potential of TLR8 Agonist GS-9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators
Oliver E. Amin et al.
HEPATOLOGY (2021)
Tumor-associated macrophage-targeted therapeutics in ovarian cancer
Yuanyuan An et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Glucose metabolism characteristics and TLR8-mediated metabolic control of CD4+ Treg cells in ovarian cancer cells microenvironment
Rui Xu et al.
CELL DEATH & DISEASE (2021)
The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent
Yinwen Cheng et al.
SCIENTIFIC REPORTS (2021)
Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma
Yang Xun et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Contradictory roles of lipid metabolism in immune response within the tumor microenvironment
Weina Yu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Combination strategies to maximize the benefits of cancer immunotherapy
Shaoming Zhu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Dysregulated tumor-associated macrophages in carcinogenesis, progression and targeted therapy of gynecological and breast cancers
Tianhan Xu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes
Wantao Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
TLR7/8 agonist treatment induces an increase in bone marrow resident dendritic cells and hematopoietic progenitor expansion and mobilization
Sidan Li et al.
EXPERIMENTAL HEMATOLOGY (2021)
Recent trends in the development of Toll-like receptor 7/8-targeting therapeutics
Xuan Huang et al.
EXPERT OPINION ON DRUG DISCOVERY (2021)
Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B
Edward J. Gane et al.
HEPATOLOGY (2021)
Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8 agonist in lung cancer model
Jiae Koh et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2021)
Macrophage polarization synergizes with oxaliplatin in lung cancer immunotherapy via enhanced tumor cell phagocytosis
Fei Li et al.
TRANSLATIONAL ONCOLOGY (2021)
Novel TLR 7/8 agonists for improving NK cell mediated antibody-dependent cellular cytotoxicity (ADCC)
Vidhi Khanna et al.
SCIENTIFIC REPORTS (2021)
Oral Selective TLR8 Agonist Selgantolimod Induces Multiple Immune Cell Responses in Humans
Natarajan Ayithan et al.
VIRUSES-BASEL (2021)
STAT3 Silencing and TLR7/8 Pathway Activation Repolarize and Suppress Myeloid-Derived Suppressor Cells From Breast Cancer Patients
Elham Safarzadeh et al.
FRONTIERS IN IMMUNOLOGY (2021)
T-cell intrinsic Toll-like receptor signaling: implications for cancer immunotherapy and CAR T-cells
Yasmin Nouri et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Immunotherapies targeting stimulatory pathways and beyond
Julian A. Marin-Acevedo et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy
Zhaonian Hao et al.
BIOMARKER RESEARCH (2021)
Next frontier in tumor immunotherapy: macrophage-mediated immune evasion
Yingqi Qiu et al.
BIOMARKER RESEARCH (2021)
Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies
Shangli Zhu et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2021)
WGCNA identification of TLR7 as a novel diagnostic biomarker, progression and prognostic indicator, and immunotherapeutic target for stomach adenocarcinoma
Qihang Yuan et al.
CANCER MEDICINE (2021)
Large, Anionic Liposomes Enable Targeted Intraperitoneal Delivery of a TLR 7/8 Agonist To Repolarize Ovarian Tumors' Microenvironment
Yanan Kang et al.
BIOCONJUGATE CHEMISTRY (2021)
Structure-Based Design of Highly Potent Toll-like Receptor 7/8 Dual Agonists for Cancer Immunotherapy
Zhisong Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
The Relationship between the Tissue Expression of TLR2, TLR4, TLR5, and TLR7 and Systemic Inflammatory Responses in Colorectal Cancer Patients
Ines Beilmann-Lehtonen et al.
ONCOLOGY (2021)
Higher TLR7 Gene Expression Predicts Poor Clinical Outcome in Advanced NSCLC Patients Treated with Immunotherapy
Sara Baglivo et al.
GENES (2021)
Follicular Helper T (T-FH) Cell Targeting by TLR8 Signaling For Improving HBsAg-Specific B Cell Response In Chronic Hepatitis B Patients
Natarajan Ayithan et al.
FRONTIERS IN IMMUNOLOGY (2021)
Intra-Tumoral Activation of Endosomal TLR Pathways Reveals a Distinct Role for TLR3 Agonist Dependent Type-1 Interferons in Shaping the Tumor Immune Microenvironment
Graham Thomas et al.
FRONTIERS IN ONCOLOGY (2021)
A Combined TLR7/TLR9/GATA3 Score Can Predict Prognosis in Biliary Tract Cancer
Vittorio Branchi et al.
DIAGNOSTICS (2021)
Advances in technology and applications of nanoimmunotherapy for cancer
Lei Dou et al.
BIOMARKER RESEARCH (2021)
High Tissue TLR5 Expression Predicts Better Outcomes in Colorectal Cancer Patients
Ines Beilmann-Lehtonen et al.
ONCOLOGY (2021)
TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages
Zhipeng Liu et al.
CANCER LETTERS (2020)
A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model
Lydia Bellmann et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Increased neutrophil extracellular traps promote metastasis potential of hepatocellular carcinoma via provoking tumorous inflammatory response
Lu-Yu Yang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Characteristics, dynamic changes, and prognostic significance of TCR repertoire profiling in patients with renal cell carcinoma
Liping Guo et al.
JOURNAL OF PATHOLOGY (2020)
Esophageal Cancer Development: Crucial Clues Arising from the Extracellular Matrix
Antonio Palumbo et al.
CELLS (2020)
Toll-like Receptors and the Control of Immunity
Katherine A. Fitzgerald et al.
CELL (2020)
Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes
Cindy Patinote et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy
Chongxian Pan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Rationally Designed Small-Molecule Inhibitors Targeting an Unconventional Pocket on the TLR8 Protein-Protein Interface
Shuangshuang Jiang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B
Richard L. Mackman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
TLR7/8 Agonist-Loaded Nanoparticles Augment NK Cell-Mediated Antibody-Based Cancer Immunotherapy
Hyunjoon Kim et al.
MOLECULAR PHARMACEUTICS (2020)
Activation of Human γδ T Cells: Modulation by Toll-Like Receptor 8 Ligands and Role of Monocytes
Ruben Serrano et al.
CELLS (2020)
Pre-activation with TLR7 in combination with thioridazine and loratadine promotes tumoricidal T-cell activity in colorectal cancer
Xiaotan Lin et al.
ANTI-CANCER DRUGS (2020)
An iRGD peptide fused superantigen mutant induced tumor-targeting and T lymphocyte infiltrating in cancer immunotherapy
Yubo Song et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2020)
High-capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma
Natasha Vinod et al.
SCIENCE ADVANCES (2020)
Crosstalks between inflammasome and autophagy in cancer
Chaeuk Chung et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
High mobility group box 1 (HMGB1): a pivotal regulator of hematopoietic malignancies
Shunling Yuan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Dendritic cell biology and its role in tumor immunotherapy
Yingying Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Plasmacytoid dendritic cells regulate colitis-associated tumorigenesis by controlling myeloid-derived suppressor cell infiltration
Eun-Hye Hong et al.
CANCER LETTERS (2020)
Development of a novel TLR8 agonist for cancer immunotherapy
Yuxun Wang et al.
MOLECULAR BIOMEDICINE (2020)
Safety, pharmacokinetics and pharmacodynamics of selgantolimod, an oral Toll-like receptor 8 agonist: a Phase Ia study in healthy subjects
Maribel Reyes et al.
ANTIVIRAL THERAPY (2020)
Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
Giorgio Frega et al.
ONCOIMMUNOLOGY (2020)
TCR repertoire intratumor heterogeneity of CD4+ and CD8+ T cells in centers and margins of localized lung adenocarcinomas
Chaoting Zhang et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Expression of toll-like receptors in non-endemic nasopharyngeal carcinoma
Miia Ruuskanen et al.
BMC CANCER (2019)
Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas
Qi Zhang et al.
GUT (2019)
Toll-like receptors TLR-2, TLR-4, TLR-7, and TLR-9 in tumor tissue and serum of the patients with esophageal squamous cell carcinoma and gastro-esophageal junction cancer
Dorota Diakowska et al.
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE (2019)
Surrogates of immunologic cell death (ICD) and chemoradiotherapy outcomes in head and neck squamous cell carcinoma (HNSCC)
Panagiota Economopoulou et al.
ORAL ONCOLOGY (2019)
Toll-like receptor 1 predicts favorable prognosis in pancreatic cancer
Mira Lanki et al.
PLOS ONE (2019)
TLR8 reprograms human Treg metabolism and function
Xia Liu et al.
AGING-US (2019)
Latest Advances in Small Molecule TLR 7/8 Agonist Drug Research
David C. McGowan
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2019)
TLR7 and TLR8 activate distinct pathways in monocytes during RNA virus infection
Marine de Marcken et al.
SCIENCE SIGNALING (2019)
The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer
Katherine A. Michaelis et al.
NATURE COMMUNICATIONS (2019)
The Role of TLRs in Anti-cancer Immunity and Tumor Rejection
Zuzanna Urban-Wojciuk et al.
FRONTIERS IN IMMUNOLOGY (2019)
TLR8-Mediated Metabolic Control of Human Treg Function: A Mechanistic Target for Cancer Immunotherapy
Lingyun Xia et al.
CELL METABOLISM (2019)
Characteristics and prognostic significance of profiling the peripheral blood T-cell receptor repertoire in patients with advanced lung cancer
Yang-Yang Liu et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Chronic TLR7 and TLR9 signaling drives anemia via differentiation of specialized hemophagocytes
Holly M. Akilesh et al.
SCIENCE (2019)
Toll like receptor 7 expressed by malignant cells promotes tumor progression and metastasis through the recruitment of myeloid derived suppressor cells
Marion Dajon et al.
ONCOIMMUNOLOGY (2019)
TLR5 and TLR7 are differentially expressed in human papillomavirus-positive and negative base of tongue squamous cell carcinoma, and TLR7 may have an independent prognostic influence
Linnea Haeggblom et al.
ACTA OTO-LARYNGOLOGICA (2019)
Malignant Melanoma Treated with Topical Imiquimod: A Bespoke Treatment That Spared the Amputation
Emanuele Verga et al.
CASE REPORTS IN DERMATOLOGY (2019)
TLR8 ligation induces apoptosis of monocytic myeloid-derived suppressor cells
Yushe Dang et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2018)
Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy
Hyunjoon Kim et al.
BIOMATERIALS (2018)
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Julian A. Marin-Acevedo et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Anti-HBV response to toll-like receptor 7 agonist GS-9620 is associated with intrahepatic aggregates of T cells and B cells
Li Li et al.
JOURNAL OF HEPATOLOGY (2018)
Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism
Congrong Niu et al.
JOURNAL OF HEPATOLOGY (2018)
Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil
Xiaodong Wang et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Antitumor Activity of TLR7 Is Potentiated by CD200R Antibody Leading to Changes in the Tumor Microenvironment
Zofia Pilch et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck The Active8 Randomized Clinical Trial
Robert L. Ferris et al.
JAMA ONCOLOGY (2018)
Dual functional roles of the MyD88 signaling in colorectal cancer development
Lu Wang et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Toll-like receptors: Important immune checkpoints in the regression of cervical intra-epithelial neoplasia 2
Gordana Halec et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Targeting Toll-Like Receptors for Cancer Therapy
Marc J. Braunstein et al.
TARGETED ONCOLOGY (2018)
The Role of Toll-Like Receptor in Inflammation and Tumor Immunity
Xiaohong Cen et al.
FRONTIERS IN PHARMACOLOGY (2018)
Prognostic role of Toll lice receptors in cancer a meta-analysis
Qingwen Wang et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2018)
Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals
Gulidanna Shayan et al.
CLINICAL CANCER RESEARCH (2018)
Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy
Bradley J. Monk et al.
CLINICAL CANCER RESEARCH (2017)
Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN
Laura Q. M. Chow et al.
CLINICAL CANCER RESEARCH (2017)
Toll-like receptor stimulation in cancer: A pro- and anti-tumor double-edged sword
Marion Dajon et al.
IMMUNOBIOLOGY (2017)
Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer
Satoshi Okazaki et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Toll-like receptors 7 and 8 expression correlates with the expression of immune biomarkers and positively predicts the clinical outcome of patients with melanoma
Moucheng Zhang et al.
ONCOTARGETS AND THERAPY (2017)
Impaired expression and function of TLR8 in chronic HBV infection and its association with treatment responses during peg-IFN-α-2a antiviral therapy
Guangying Deng et al.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY (2017)
Tumor-associated macrophages, potential targets for cancer treatment
Li Yang et al.
BIOMARKER RESEARCH (2017)
A phase 2, randomized, double-blind, placebo-controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study
B. J. Monk et al.
ANNALS OF ONCOLOGY (2017)
Oligodeoxynucleotide inhibition of Toll-like receptors 3, 7, 8, and 9 suppresses cytokine production in a human rheumatoid arthritis model
Sandra Sacre et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2016)
Cancer-associated toll-like receptor modulation and insinuation in infection susceptibility: association or coincidence?
A. A. Khan et al.
ANNALS OF ONCOLOGY (2016)
Associations of microbiota and toll-like receptor signaling pathway in esophageal adenocarcinoma
Ali H. Zaidi et al.
BMC CANCER (2016)
Lung tumor exosomes induce a pro-inflammatory phenotype in mesenchymal stem cells via NFκB-TLR signaling pathway
Xiaoxia Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial
Ivan Fan-Ngai Hung et al.
LANCET INFECTIOUS DISEASES (2016)
Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod
Richard W. Joseph et al.
MELANOMA RESEARCH (2016)
Decreased expression of TLR7 in gastric cancer tissues and the effects of TLR7 activation on gastric cancer cells
Jiong Jiang et al.
ONCOLOGY LETTERS (2016)
Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy
Simon J. Dovedi et al.
ONCOTARGET (2016)
Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity
Gregory N. Dietsch et al.
PLOS ONE (2016)
Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma
Alain H. Rook et al.
BLOOD (2015)
Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337)
Gregory N. Dietsch et al.
CLINICAL CANCER RESEARCH (2015)
Distinct expression patterns of Toll-like receptor 7 in tumour cells and fibroblast-like cells in oral squamous cell carcinoma
Yan Hong Ni et al.
HISTOPATHOLOGY (2015)
TLR7 and TLR8 expression increases tumor cell proliferation and promotes chemoresistance in human pancreatic cancer
Tanja Grimmig et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Local administration of a novel Toll-like receptor 7 agonist in combination with doxorubicin induces durable tumouricidal effects in a murine model of T cell lymphoma
Jiang Zhu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B
Stephan Menne et al.
JOURNAL OF HEPATOLOGY (2015)
Toll-like receptor 7/8 agonist, R848, exhibits antitumoral effects in a breast cancer model
Tao Yin et al.
MOLECULAR MEDICINE REPORTS (2015)
Resiquimod—a topical CTCL therapy
David Killock
Nature Reviews Clinical Oncology (2015)
Conjugation of toll-like receptor-7 agonist to gastric cancer antigen MG7-Ag exerts antitumor effects
Xiao-Dong Wang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Dual roles of TLR7 in the lung cancer microenvironment
Marion Dajon et al.
ONCOIMMUNOLOGY (2015)
Preliminary study on the expression of Toll-like receptors 7 and 8 in bladder urothelial tumors
Gianmarco Garau et al.
UROLOGIA JOURNAL (2015)
TLR7 Promotes Tumor Progression, Chemotherapy Resistance, and Poor Clinical Outcomes in Non-Small Cell Lung Cancer
Saradiya Chatterjee et al.
CANCER RESEARCH (2014)
Microbiome, Innate Immunity, and Esophageal Adenocarcinoma
Jonathan Baghdadi et al.
CLINICS IN LABORATORY MEDICINE (2014)
Novel drugs targeting Toll-like receptors for antiviral therapy
Mira C. Patel et al.
FUTURE VIROLOGY (2014)
Toll-like receptor signaling in colorectal cancer: carcinogenesis to cancer therapy
Ting-Ting Li et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Toll-like receptor signaling pathways
Takumi Kawasaki et al.
FRONTIERS IN IMMUNOLOGY (2014)
Toll-like receptor-4 modulation for cancer immunotherapy
Shanjana Awasthi
FRONTIERS IN IMMUNOLOGY (2014)
Beyonc MyD88 and TRIF pathways in Toll-like receptor signaling
Vincent Piras et al.
FRONTIERS IN IMMUNOLOGY (2014)
Assembly and localization of Toll-like receptor signalling complexes
Nicholas J. Gay et al.
NATURE REVIEWS IMMUNOLOGY (2014)
TLR agonists: our best frenemy in cancer immunotherapy
Sabina Kaczanowska et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2013)
Structural Reorganization of the Toll-Like Receptor 8 Dimer Induced by Agonistic Ligands
Hiromi Tanji et al.
SCIENCE (2013)
Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies
Brenda J. Weigel et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Roles of toll-like receptors in Cancer: A double-edged sword for defense and offense
Shaherin Basith et al.
ARCHIVES OF PHARMACAL RESEARCH (2012)
VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
Hailing Lu et al.
CLINICAL CANCER RESEARCH (2012)
Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans
Atsuo Ochi et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Accessory molecules for Toll-like receptors and their function
Clarissa C. Lee et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Infectious Diseases in Patients with IRAK-4, MyD88, NEMO, or IκBα Deficiency
Capucine Picard et al.
CLINICAL MICROBIOLOGY REVIEWS (2011)
Increased Toll-like receptor 9 expression indicates adverse prognosis in oesophageal adenocarcinoma
Joonas H. Kauppila et al.
HISTOPATHOLOGY (2011)
Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and Immunity
Taro Kawai et al.
IMMUNITY (2011)
Toll-Like Receptor 9 Is a Novel Biomarker for Esophageal Squamous Cell Dysplasia and Squamous Cell Carcinoma Progression
Heikki Takala et al.
JOURNAL OF INNATE IMMUNITY (2011)
Epithelial crosstalk at the microbiota-mucosal interface
Jerry M. Wells et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma
Ilyar Sheyhidin et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2011)
Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers
Melissa A. Geller et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
A five-amino-acid motif in the undefined region of the TLR8 ectodomain is required for species-specific ligand recognition
Jin Liu et al.
MOLECULAR IMMUNOLOGY (2010)
Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study
Alexandre Carpentier et al.
NEURO-ONCOLOGY (2010)
Toll-Like Receptors, Tissue Injury, and Tumourigenesis
Savvas Ioannou et al.
MEDIATORS OF INFLAMMATION (2010)
Toll-like receptor expression in normal ovary and ovarian tumors
Mingfu Zhou et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Pathogen recognition receptors, cancer and inflammation in the gut
Masayuki Fukata et al.
CURRENT OPINION IN PHARMACOLOGY (2009)
Up-regulated expression of Toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus
A. Komatsuda et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2008)
An exploratory study of systemic administration of the Toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma
Reinhard Dummer et al.
CLINICAL CANCER RESEARCH (2008)
Synthetic agonists of Toll-like receptors 7, 8 and 9
S. Agrawal et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2007)
Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines
Keith K. B. Gorden et al.
JOURNAL OF IMMUNOLOGY (2006)
Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists
Kevin S. Gorski et al.
INTERNATIONAL IMMUNOLOGY (2006)
The Expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells
MF Roelofs et al.
ARTHRITIS AND RHEUMATISM (2005)
TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-γ production
OM Hart et al.
JOURNAL OF IMMUNOLOGY (2005)
Differential capability for phagocytosis of apoptotic and necrotic leukemia cells by human peripheral blood dendritic cell subsets
J Dalgaard et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2005)
Synthetic TLR Agonists reveal functional differences between human TLR7 and TLR8
KB Gorden et al.
JOURNAL OF IMMUNOLOGY (2005)
Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848
M Jurk et al.
NATURE IMMUNOLOGY (2002)
Quantitative expression of Toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides
V Hornung et al.
JOURNAL OF IMMUNOLOGY (2002)